Bovilis Blue-8

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

bluetongue virus vaccine, serotype 8 (inactivated)

Available from:

Intervet International B.V.

ATC code:

QI04AA02

INN (International Name):

bluetongue virus vaccine (inactivated) serotype 8

Therapeutic group:

Cattle; Sheep

Therapeutic area:

Immunologicals for ovidae

Therapeutic indications:

SheepFor the active immunisation of sheep from 2.5 months of age to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.CattleFor the active immunisation of cattle from 2.5 months of age to prevent viraemia* caused by bluetongue virus serotype 8.*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome)

Product summary:

Revision: 4

Authorization status:

Authorised

Authorization date:

2017-11-21

Patient Information leaflet

                                16
B. PACKAGE LEAFLET
page 16 of 20
17
PACKAGE LEAFLET:
BOVILIS BLUE-8 SUSPENSION FOR INJECTION FOR CATTLE AND SHEEP
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Intervet International BV
Wim de Körverstraat 35,
5831 AN Boxmeer
The NETHERLANDS
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis Blue-8 suspension for injection for cattle and sheep
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each ml of vaccine contains:
Bluetongue virus inactivated, serotype 8
10
6.5
CCID
50
*
Aluminium hydroxide
6 mg
Purified saponin (Quil A)
0.05 mg
Thiomersal
0.1 mg
(* equivalent to titre prior to inactivation)
4.
INDICATION(S)
Sheep
For the active immunisation of sheep from 2.5 months of age to prevent
viraemia* and to reduce
clinical signs caused by bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
20 days after the second dose.
Duration of immunity:
1 year after the second dose.
Cattle
For the active immunisation of cattle from 2.5 months of age to
prevent viraemia* caused by
bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
31 days after the second dose.
Duration of immunity:
1 year after the second dose.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
An average increase in body temperature varying between 0.5 and 1.0
ºC is a common reaction
observed in sheep and cattle. It lasted not longer than 24 to 48
hours. Transient fever was observed in
rare cases. Temporary local reactions can occur very rarely at the
injection site in the form of a nodule
page 17 of 20
18
of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears
within 14 days, at the latest and
which may be painful. Loss of appetite can occur in very rare cases.
Hypersensitivity reactions are
very rarely observed.
The frequency of adverse re
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
page 1 of 20
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis Blue-8 suspension for injection for cattle and sheep
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of vaccine contains:
ACTIVE SUBSTANCE:
Bluetongue virus inactivated, serotype 8: 10
6.5
CCID
50
*
(* equivalent to titre prior to inactivation)
ADJUVANTS:
Aluminium hydroxide
6 mg
Purified saponin (Quil A) 0.05 mg
EXCIPIENT:
Thiomersal
0.1 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
White or pinkish-white.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Sheep and cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Sheep
For the active immunisation of sheep from 2.5 months of age to prevent
viraemia* and to reduce
clinical signs caused by bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
20 days after the second dose.
Duration of immunity:
1 year after the second dose.
Cattle
For the active immunisation of cattle from 2.5 months of age to
prevent viraemia* caused by
bluetongue virus serotype 8.
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating
no presence of viral genome)
Onset of immunity:
31 days after the second dose.
Duration of immunity:
1 year after the second dose.
4.3
CONTRAINDICATIONS
None.
page 2 of 20
3
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
Occasionally, the presence of maternally derived antibodies in ovines
of minimum recommended age
might interfere with the protection induced by the vaccine.
No information is available on the use of the vaccine in seropositive
bovines, including those with
maternally derived antibodies.
If used in other domestic and wild ruminant species that are
considered at risk of infection, its use in
these species should be undertaken with care and it is advisable to
test the vaccine on a small number
of animals prior to mass vaccination. The level of
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-12-2021
Public Assessment Report Public Assessment Report Bulgarian 08-12-2017
Patient Information leaflet Patient Information leaflet Spanish 20-12-2021
Public Assessment Report Public Assessment Report Spanish 08-12-2017
Patient Information leaflet Patient Information leaflet Czech 20-12-2021
Public Assessment Report Public Assessment Report Czech 08-12-2017
Patient Information leaflet Patient Information leaflet Danish 20-12-2021
Public Assessment Report Public Assessment Report Danish 08-12-2017
Patient Information leaflet Patient Information leaflet German 20-12-2021
Public Assessment Report Public Assessment Report German 08-12-2017
Patient Information leaflet Patient Information leaflet Estonian 20-12-2021
Public Assessment Report Public Assessment Report Estonian 08-12-2017
Patient Information leaflet Patient Information leaflet Greek 20-12-2021
Public Assessment Report Public Assessment Report Greek 08-12-2017
Patient Information leaflet Patient Information leaflet French 20-12-2021
Public Assessment Report Public Assessment Report French 08-12-2017
Patient Information leaflet Patient Information leaflet Italian 20-12-2021
Public Assessment Report Public Assessment Report Italian 08-12-2017
Patient Information leaflet Patient Information leaflet Latvian 20-12-2021
Public Assessment Report Public Assessment Report Latvian 08-12-2017
Patient Information leaflet Patient Information leaflet Lithuanian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-12-2021
Public Assessment Report Public Assessment Report Lithuanian 08-12-2017
Patient Information leaflet Patient Information leaflet Hungarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 20-12-2021
Public Assessment Report Public Assessment Report Hungarian 08-12-2017
Patient Information leaflet Patient Information leaflet Maltese 20-12-2021
Public Assessment Report Public Assessment Report Maltese 08-12-2017
Patient Information leaflet Patient Information leaflet Dutch 20-12-2021
Public Assessment Report Public Assessment Report Dutch 08-12-2017
Patient Information leaflet Patient Information leaflet Polish 20-12-2021
Public Assessment Report Public Assessment Report Polish 08-12-2017
Patient Information leaflet Patient Information leaflet Portuguese 20-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 20-12-2021
Public Assessment Report Public Assessment Report Portuguese 08-12-2017
Patient Information leaflet Patient Information leaflet Romanian 20-12-2021
Public Assessment Report Public Assessment Report Romanian 08-12-2017
Patient Information leaflet Patient Information leaflet Slovak 20-12-2021
Public Assessment Report Public Assessment Report Slovak 08-12-2017
Patient Information leaflet Patient Information leaflet Slovenian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 20-12-2021
Public Assessment Report Public Assessment Report Slovenian 08-12-2017
Patient Information leaflet Patient Information leaflet Finnish 20-12-2021
Public Assessment Report Public Assessment Report Finnish 08-12-2017
Patient Information leaflet Patient Information leaflet Swedish 20-12-2021
Public Assessment Report Public Assessment Report Swedish 08-12-2017
Patient Information leaflet Patient Information leaflet Norwegian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 20-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 20-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 20-12-2021
Patient Information leaflet Patient Information leaflet Croatian 20-12-2021
Public Assessment Report Public Assessment Report Croatian 08-12-2017

View documents history